期刊
CLINICAL CASE REPORTS
卷 9, 期 8, 页码 -出版社
WILEY
DOI: 10.1002/ccr3.4625
关键词
CGRP monoclonal antibodies; chronic migraine; erenumab; Raynaud's phenomenon
Raynaud's phenomenon is a rare side effect of CGRP monoclonal antibodies, and patients with a background of Raynaud's phenomenon may experience worsening of their symptoms if started on these treatments in the future.
Raynaud's phenomenon is a rare side effect of CGRP monoclonal antibodies. These molecular treatments are a relatively new class of drugs for the prevention of migraine. It is likely that we will see this side effect more often in the future. Patients with a background of Raynaud's phenomenon may experience worsening of their symptoms if started on these treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据